Assessing Disease Progression in MSA: Development of a Bayesian Progression Model
Objective: Develop a Bayesian progression model (BPM) for MSA that leverages individual-level data derived from long-term follow up and offers a clinically interpretable, slope-based primary…PET and Clinical Evidence for Neuroprotective Effects of KM-819 on MSA
Objective: To assess the effect of KM-819 on the progression of multiple system atrophy (MSA). Background: Parkinson’s brain is associated with increased expression of the…Differences Between Clinical and Imaging Phenotypes in Phase 2 Study of ATH434 in Multiple System Atrophy
Objective: To assess differences between clinical and imaging phenotypes in Multiple System Atrophy (MSA) and evaluate the reliability of imaging biomarkers for subtype classification. Background:…Integrated Management of atypical Parkinsonism: A home-based patient-Centered healthcare model using Telenursing. Baseline data from the Multicentre IMPACT study
Objective: To evaluate the effectiveness of a telemedicine-based (‘Telenursing’) home healthcare model, coordinated by a Parkinsonism Nurse Specialist (PKNS), in improving the quality of life…A Randomized, Double-blind Phase 3 Trial of Amlenetug Versus Placebo in Patients with MSA: The MASCOT Trial
Objective: Describe the protocol for a randomized, double-blind phase 3 trial evaluating the efficacy and safety of amlenetug versus placebo in slowing clinical progression in…Incorporating Patient and Care Partner Feedback on the Protocol for a Clinical Trial Assessing Progression in MSA
Objective: Describe the perspectives of people living with MSA (PwMSA) and their care partners on the design and operational characteristics of a phase 3 trial…The IMPACT study: protocol of a randomised controlled single-blind trial evaluating efficacy and cost-effectiveness of telenursing in atypical parkinsonism
Objective: To present the protocol of a study evaluating the efficacy and cost-effectiveness of a 12-month integrated program aimed at improving healthcare delivery and coordinated…Intrathecal Administration of Human Oral Mucosa Neural Crest Stem Cells in Moderate/Advanced Multiple System Atrophy: Report on Ongoing Phase 1 Study
Objective: This first-in-human study aims to evaluate the safety of hOMNSC300 following intrathecal administration in patients with moderate to advanced MSA. Background: Stem cell therapy…ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy
Objective: Evaluate the efficacy and safety of ATH434 treatment in individuals with MSA Background: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder without…The effectiveness and safety of autologous adipose derived stromal vascular components (SVF) in the treatment of multiple system atrophy
Objective: This study aimed to explore the efficacy and safety of autologous adipose - derived stromal vascular fraction (SVF) in treating MSA. Background: Multisystem atrophy…
- 1
- 2
- 3
- …
- 8
- Next Page »